Little Stemline grabs a big ‘breakthrough’ title for its pivotal-stage cancer drug
Back at the big ASCO meeting in Chicago last June, little New York-based Stemline Therapeutics $STML was largely left on the sidelines by a few …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
